Exicure, Inc. Sees Significant Drop in Short Interest in February

Exicure, Inc. experienced a notable decrease in short interest during February 2024. As of February 13, the biotechnology company’s short interest totaled **62,840 shares**, reflecting a **28.5% decline** from the previous total of **87,833 shares** recorded on January 29. This reduction indicates that approximately **2.1%** of Exicure’s stock is currently sold short. The short-interest ratio now stands at **1.9 days**, based on an average daily trading volume of **33,193 shares**.

Insider Activity and Shareholder Movements

In related developments, major shareholder **Sangsangin Investment & Securi** sold **433,332 shares** of Exicure on **December 8, 2023**. The shares were sold at an average price of **$8.71**, resulting in a substantial transaction value of **$3,774,321.72**. This transaction was disclosed through a legal filing with the SEC, which is publicly accessible. Currently, insiders own **52.80%** of Exicure’s stock.

Analysts have also weighed in on Exicure’s shares recently. **Wall Street Zen** upgraded the stock to a “hold” rating in a research note dated **January 17, 2024**. Conversely, **Weiss Ratings** maintained a “sell (e+)” rating in a note published on **December 29, 2023**. Overall, data from **MarketBeat.com** indicates that Exicure has an average rating of “Sell,” with one research analyst specifically rating the stock as a sell.

Current Stock Performance

On February 12, shares of Exicure opened at **$3.74**. Over the past year, the stock has fluctuated between a low of **$3.10** and a high of **$15.91**. Exicure currently holds a market capitalization of **$23.82 million**, a price-to-earnings ratio of **-1.01**, and a beta of **4.13**. The company’s stock has a 50-day simple moving average of **$4.98** and a 200-day simple moving average of **$4.86**.

Exicure is recognized as a clinical-stage biotechnology firm that focuses on creating next-generation genetic medicines utilizing its proprietary **spherical nucleic acid (SNA)** delivery platform. This innovative nanotechnology aims to enhance the intracellular delivery of oligonucleotide therapeutics, addressing challenges in targeting difficult tissues, including the central nervous system. The company’s pipeline includes programs aimed at neurological disorders such as **Huntington’s disease**, **Parkinson’s disease**, and **Alzheimer’s disease**, along with exploratory efforts in dermatological conditions and oncology.

For those interested in receiving timely updates and ratings on Exicure and other related companies, a free daily email newsletter is available through MarketBeat.com, summarizing the latest news and analyst insights.